FDG-PET imaging may have a place for staging primary hepatic malignancies in children.
FDG-PET imaging may have a place for staging primary hepatic malignancies in children.
Dr. Rajen J. Mody and colleagues at the University of Michigan Health System, Ann Arbor, imaged seven children with pathologically proven hepatic malignancies. Six of the seven exhibited abnormal FDG uptake. Liver tumor was confirmed in three patients who underwent partial hepatic resection and in one patient who had a brain biopsy. Uptake in one patient was due to necrotizing granulomas, and another patient's images were suboptimal due to noncompliance with fasting.
The researchers concluded that FDG-PET imaging in pediatrics is most useful to assess response to therapy, in following alfa fetoprotein-negative cases, and for detecting metastatic disease. The study appeared in Pediatric Blood & Cancer (published online Aug. 2 ahead of print).
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.